Tumor markers and their role: a complete guide for patients and implications for therapy

Have you received a blood test with an elevated “tumor marker” and are you scared? Or has your doctor asked you to monitor a marker during treatment and you don’t understand why? This guide translates into simple words what tumor markers are, what their values mean, and — most importantly — how they help guide oncology treatment. The reassuring news: tumor markers are used much more often for treatment monitoring , not for diagnosis.

1. What are tumor markers?

Tumor markers are biochemical substances (usually proteins) produced either by cancer cells or by the body in response to the presence of a tumor. They can be measured in blood, urine, or even tissue.

It is essential to understand a basic principle, valid in 2026: tumor markers should NOT be used for screening in healthy, asymptomatic individuals (the only exception being PSA, after a discussion with a doctor). A slightly elevated value — for example, an elevated CEA in a smoker — does not mean cancer, but may generate anxiety and unnecessary investigations.

• An elevated marker alone does not confirm cancer.
• A normal marker does not completely rule out the disease.
• The trend over time (whether the value increases or decreases with repeated measurements) is much more important than a single isolated value.

2. Guide to the most important tumor markers

Here is a simple table with the most commonly encountered markers, their reference values, and their actual role. Keep in mind that these values may vary slightly from one laboratory to another.

Marker	Normal value	What cancer is it associated with?
CEA (carcinoembryonic antigen)	≤3 ng/mL (non-smokers); ≤5 ng/mL (smokers)	Colorectal, pancreatic, gastric, pulmonary
AFP (alpha-fetoprotein)	≤10 ng/mL	Liver cancer (HCC), germinal tumors
PSA (prostate specific antigen)	<4.0 ng/mL	Prostate cancer
CA 125	<35 U/mL	Ovarian cancer
CA 19-9	<37 U/mL	Pancreatic, biliary cancer
CA 15-3	<30 U/mL	Breast cancer (monitoring)
HE4	<70 pmol/L (premenopause)	Ovarian, endometrial cancer
Calcitonin	<5 pg/mL (F); <8.4 pg/mL (B)	Medullary thyroid cancer

Why are these ranges important? Because intermediate values often have benign causes . For example, CA 125 between 35 and 200 U/mL may occur in endometriosis or cirrhosis, while values above 200 U/mL raise suspicion of ovarian cancer. Likewise, CA 19-9 between 37 and 100 U/mL may reflect simple pancreatic or biliary inflammation.

3. One detail that changes everything: we don’t all produce markers

A surprising fact that few patients know: approximately 5–10% of the population has the “Lewis-null” blood type and cannot synthesize CA 19-9 at all — no matter how large the tumor is. Similarly, over 10% of patients with liver cancer do not have elevated AFP. This is why no marker is interpreted in isolation, but always in a clinical context, along with imaging and biopsy.

4. Central role: monitoring treatment and detecting relapses

This is where the true value of tumor markers lies. They function as a “barometer” of the effectiveness of therapy:

• A decrease in the marker under treatment (surgery, chemotherapy) indicates a good therapeutic response . For example, CEA usually normalizes within 4–6 weeks after successful surgical resection.
• A rise in the value again after normalization may signal a relapse , often months before it becomes visible on imaging.

Some concrete examples from practice updated to 2026:

• HE4 can detect ovarian cancer recurrence an average of 126 days earlier than clinical confirmation, being elevated in 75% of recurrent cases (compared to only 50% for CA 125).
• AFP has a “half-life” of 3.5–5 days in germ cell tumors. If it does not decline at this rate after treatment begins, doctors suspect chemotherapy resistance.
• In ovarian cancer, achieving a normal CA 125 after chemotherapy is a strong prognostic factor: in a recent study, patients with normal CA 125 had a progression-free survival rate of 72% at 6 months, compared to 25% in those with elevated values.

5. Implications in choosing personalized therapy

Tumor markers don’t just monitor — they guide therapeutic decisions . Here’s how certain values are linked to specific treatments, according to the NCCN and ESMO 2026 international guidelines:

• In pancreatic cancer , a CA 19-9 above 500 U/mL at diagnosis predicts poorer resectability, directing the doctor towards chemotherapy (FOLFIRINOX) before surgery.
• In medullary thyroid cancer , both calcitonin and CEA are monitored together, as a calcitonin doubling time of less than 6 months indicates aggressive disease.
• In liver cancer , the GALAD score (which combines sex, age, AFP-L3%, AFP, and DCP) achieves a sensitivity of 60–80% for early detection, superior to AFP used alone.

How Artificial Intelligence helps interpret markers

The complete tumor marker profile generates a huge amount of data, and international treatment protocols are updated from one month to the next. This is where the value of the Oncoexpertai platform comes in . Unlike a simple reading of the results, our advanced Artificial Intelligence algorithms instantly correlate the values of your markers (CEA, CA 125, PSA, CA 19-9 and others) with thousands of clinical studies and international oncology guidelines updated in real time (NCCN / ESMO). The technology does not replace the doctor, but gives him the certainty that the proposed treatment regimen is the most effective for your specific profile.

If you just want a completely free opinion without uploading any medical documents, use one of the 2 orange boxes “Talk to Dr. Onisim” or green “Message to Dr. Onisim”

---

Disclaimer: The information in this article is for informational and educational purposes only. It is not a substitute for the consultation, diagnosis, or treatment provided by a qualified medical professional. For any decision regarding your health, always consult a medical professional.

---

Bibliography

1. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2024;35(2):159–182. doi: 10.1016/j.annonc.2023.11.016
2. Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(11):987–1002. doi: 10.1016/j.annonc.2023.08.009
3. González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(10):833–848. doi: 10.1016/j.annonc.2023.07.011
4. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. doi: 10.1097/HEP.0000000000000466
5. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(1):10–32. doi: 10.1016/j.annonc.2022.10.003
6. Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(9):1119–1134. doi: 10.1016/j.annonc.2020.06.011
7. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019;30(12):1856–1883. doi: 10.1093/annonc/mdz400

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI